Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 10,4 M
EBIT 2017 -17,3 M
Net income 2017 -17,1 M
Finance 2017 0,75 M
Yield 2017 -
Sales 2018 24,0 M
EBIT 2018 7,00 M
Net income 2018 5,00 M
Finance 2018 6,00 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 20,75
EV / Sales2017 11,2x
EV / Sales2018 4,63x
Capitalization 117 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
04/19Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
03/07 ONXEO : Full-year 2016 Results and Outlook for 2017
03/02ONXEO SA : annual earnings release
03/01 ONXEO : Appoints Seasoned Executives to Accelerate Preclinical and Clinical Deve..
02/17 ONXEO : Drugs for Herpes Labialis Market 2017 - GSK, Novartis, Teva, Apotex, Cad..
02/13 ONXEO : receives USPTO Notice of Allowance for a new AsiDNA™-related paten..
02/08 ONXEO : Information on ReLive Trial Design and Role of its Data Safety and Monit..
01/06 EQS-NEWS : Edison issues outlook on Onxeo (ONXEO)
2016 ONXEO : to Attend Two French Investor Conferences in January
2016 ONXEO : Strengthens AsiDNA Patent Protection in Europe
2016 ONXEO : to Participate in the Guggenheim Securities 4th Annual Boston Healthcare..
More news
Sector news : Pharmaceuticals - NEC
09:30a TEVA PHARM MAY FIRE 6,000 WORKERS : Israeli media report
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 8,10 €
Spread / Average Target 225%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Françoise Bono Chief Scientific Officer
Olivier de Beaumont Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA127
JOHNSON & JOHNSON9.59%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.6.13%205 273
NOVARTIS AG0.47%194 072
MERCK & CO., INC.7.86%174 344
More Results